RemeGen is a China-based biopharmaceutical company focused on the research, development, manufacturing, and sale of biologics, antibody-drug conjugates, and other pharmaceutical products geared at combating cancer, eye disorders, and autoimmune-related diseases.
The Yantai, Shandong-based company develops, manufactures, and commercializes biopharmaceutical products to help treat life-threatening diseases. RemeGen was started in 2008 by Harvard Medical School-trained, Canada-educated scientist Jianmin Fang. He started the company after he convinced some of his co-workers at a Chinese medicine company to join him in launching a biologics company. Fang was the first CEO and CSO of the company, and still serves in these capacities.
To meet its goals, RemeGen recently went public on the Hong Kong exchange and raised over $515 million in one of the biggest initial public offerings (IPOs) ever witnessed in the biotech industry.
RemeGen’s IPO was the biggest for a biopharma company in the biotech space this year and the second-largest ever after Moderna Therapeutics’ $600 million IPO in 2018. Other biopharmaceutical companies with substantial initial public offerings this year include Hepalink (raised $491M), Simcere (raised $461M), Everest Med (raised $451M), Legend Bio (raised $424M), Relay Tx (raised $400M), and Genor Pharma (raised $371M).
The cash raised from the IPO will be reinvested into the company to further develop an array of drugs already in their pipeline. RemeGen already filed a New Drug Application for its systemic lupus erythematosus drug Telitacicept, which, if approved, would be a game-changer as the first lupus medication released in decades.
RemeGen certainly has a lot to offer its investors as the future looks bright for the company and the line of medications it is working on rolling out in the near future. From antibody-drug conjugates anchored by RC18, to fusion proteins and Telitacicept, RemeGen is surging full-speed ahead.
Another possible game-changer in RemeGen’s pipeline is an ADC that targets the HER2 protein in cancer victims. Disitamab vedotin or RC48 is RemeGen’s step into the big leagues, allowing them to stand amid industry giants like AstraZeneca and Daiichi Sankyo.
RemeGen’s path differs from other companies in the making of ADCs in that, while Tukysa by Seattle Genetics and Enhertu by AstraZeneca and Daiichi Sankyo focus more on breast cancer, RemeGen’s Disitamab Vedotin instead focuses on urothelial cancer and gastric cancer.
The capital influx provided by biopharmaceutical IPOs continues to provide the world with more powerful and effective medications and diagnoses. RemeGen is one of the companies behind these innovations, proving itself as a leader in the industry.
